Abstract
CONGRESS COVERAGE: Renal Sympathetic Denervation for Resistant Hypertension: Symplicity HTN-3 and the Power of Placebo
Highlights
The results of the Symplicity HTN-3 trial have been presented a few days ago in the 2014 Scientific Meeting of the American College of Cardiology and simultaneously published in the New England Journal of Medicine [1]
The Symplicity HTN-3 trial was the first placebo-controlled study evaluating the effects of renal sympathetic denervation (RSD) in patients with resistant hypertension
The Symplicity HTN-3 trial was a multicenter, prospective, randomized, single-blind, sham-controlled study conducted in the United States of America
Summary
The results of the Symplicity HTN-3 trial have been presented a few days ago in the 2014 Scientific Meeting of the American College of Cardiology and simultaneously published in the New England Journal of Medicine [1]. Renal Sympathetic Denervation for Resistant Hypertension: Symplicity HTN-3 and the Power of Placebo
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
